Arrowhead Pharmaceuticals (ARWR) Accumulated Depreciation & Amortization (2016 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $6.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 25.0% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Dec 2025, up 25.0%, and an annual FY2025 reading of $22.2 million, up 31.36% over the prior year.
- Accumulated Depreciation & Amortization was $6.0 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $22.2 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $22.2 million in Q3 2025 and bottomed at $1.6 million in Q2 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $6.9 million, with a median of $4.6 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization crashed 44.83% in 2021, then skyrocketed 268.18% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $2.1 million in 2021, then increased by 9.52% to $2.3 million in 2022, then surged by 65.22% to $3.8 million in 2023, then increased by 26.32% to $4.8 million in 2024, then increased by 25.0% to $6.0 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ARWR at $6.0 million in Q4 2025, $22.2 million in Q3 2025, and $16.2 million in Q2 2025.